CRISPR THERAPTC (NASDAQ:CRSP) reported earnings this Afternoon, coming in at ($0.56) per share, beating Wall Street’s estimates of ($0.62) per Share. Revenue for the quarter came in at $3.60 million beating analyst estimates of $3.29 million
Analyst Coverage For CRISPR THERAPTC (NASDAQ:CRSP)
These are 4 Hold Ratings, 4 Buy Ratings .
The current consensus rating for CRISPR THERAPTC (NASDAQ:CRSP) is Buy (Score: 2.50) with a consensus target price of $21.92 , a potential (23.13% upside)Recent Insider Trading for CRISPR THERAPTC (NASDAQ:CRSP)
- On 8/8/2017 Kurt Von Emster, Director, sold 35,473 with an average share price of $18.63 per share and the total transaction amounting to $660,861.99.
- On 8/8/2017 Tyler Dylan-Hyde, Insider, sold 15,000 with an average share price of $18.57 per share and the total transaction amounting to $278,550.00.
- On 8/4/2017 Kurt Von Emster, Director, sold 50,477 with an average share price of $17.81 per share and the total transaction amounting to $898,995.37.
- On 8/1/2017 Kurt Von Emster, Director, sold 5,512 with an average share price of $17.51 per share and the total transaction amounting to $96,515.12.
- On 7/28/2017 Kurt Von Emster, Director, sold 41,312 with an average share price of $17.63 per share and the total transaction amounting to $728,330.56.
- On 7/26/2017 Kurt Von Emster, Director, sold 32,930 with an average share price of $17.60 per share and the total transaction amounting to $579,568.00.
Recent Trading for CRISPR THERAPTC (NASDAQ:CRSP) Shares of CRISPR THERAPTC closed the previous trading session at 17.80 up +0.23 1.31% with 132,589 shares trading hands.